Issue Information
Conditioning regimens for autologous haematopoietic stem cell transplantation – can natural killer cell therapy help?
Prognosis and risk assessment in AL amyloidosis – There and back again
Bone marrow erythrophagocytosis and reticulocytopenia in autoimmune haemolytic anaemia
Cryptic 5q deletion in a patient with myelodysplastic syndrome
Immunotherapy for infectious diseases in haematological immunocompromise
Granulocyte transfusions in the management of invasive fungal infections
Iron chelation therapy in low risk myelodysplastic syndrome
The six‐minute walk test in patients with AL amyloidosis : a single centre case series
Diagnostic value of whole‐body ultra‐low dose computed tomography in comparison with spinal magnetic resonance imaging in the assessment of disease in multiple myeloma
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age : secondary analysis from the phase 3 ASPIRE study
Measurement of BCR‐ABL1 by RT‐qPCR in chronic myeloid leukaemia : findings from an International EQA Programme
The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine‐expressing myeloma cells
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma : final analysis of the phase II RevLite study
Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014 : an analysis of the Swedish Lymphoma Registry
Phase I study of cord blood‐derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma
A phase 1 trial of temsirolimus and intensive re‐induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia : a Children's Oncology Group study (ADVL1114)
Thrombopoetin receptor agonist therapy in thrombocytopenia : ITP and beyond
The six‐minute walk test is a valuable measure of functional change following chemotherapy for AL (light‐chain) cardiac amyloidosis
Changes in autonomic nervous activity during vaso‐occlusive crisis in patients with sickle cell anaemia
Idelalisib‐Rituximab induces clinical remissions in patients with TP53 disrupted B cell prolymphocytic leukaemia
MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma
Real world experience of bortezomib re‐treatment for patients with multiple myeloma at first relapse
Announcements : MEETINGS AND CONFERENCES ‐ Forthcoming Event